Tetanus Antitoxoid Antibodies
Also known as: Tetanus Toxin Antibodies
Use
Assess immunity against tetanus by determining levels of circulating antibodies to tetanus toxin or to measure the immune response, postvaccination, in individuals suspected of immunodeficiency disorders
Special Instructions
The determination of tetanus toxoid antibodies is used for assessing immunity and should not be used for prophylactic or therapeutic decision-making. Immunity can decline over time, typically requiring booster shots every 10 years. It is important to note that this procedure may be considered investigational by Medicare and certain other carriers, which may affect coverage and reimbursement for patients.
Limitations
Determination of tetanus toxoid antibodies through this test does not provide information on whether prophylactic or therapeutic measures are needed. Immunity levels decrease with age, necessitating regular booster vaccinations. Additionally, some carriers might classify this test as investigational, potentially impacting coverage. The assay's results should only be used for research purposes as the performance characteristics have not been definitively established, and further confirmation with a medically accepted diagnostic product is advised.
Methodology
Immunoassay (EIA)
Biomarkers
LOINC Codes
- 53935-3
- 53935-3
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Storage Instructions
Room temperature
Causes for Rejection
Gross hemolysis; lipemia; bacterial contamination
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |